Abstracts

NOVEL IMMUNOTHERAPY-BASED CURE INTERVENTIONS

The development of single-pill anti-retroviral therapies (ART) with tolerable toxicity profiles have proven highly effective in suppressing HIV viremia to clinically undetectable levels in people living with HIV (PLWH). However, ART alone is incapable of purging the pool of long-lived, tissue-resident, quiescent CD4+ T-cells harboring latent, replication-competent viral genomes. These ‘viral reservoirs’, maintained despite ART,…

A NEW ERA FOR TREATMENT OF MULTI-DRUG RESISTANT TUBERCULOSIS

After decades of treating drug-resistant tuberculosis with 18-24 month regimens of highly unpleasant multi-drug regimens consisting of 5-8 agents including an ototoxic daily injectable drug, achieving treatment success in less than half of all patients, we are entering a new therapeutic era. New and repurposed agents are important but the laboratory and clinical science underpinning…

THE PROMISE OF NEW DRUGS AND LONG-ACTING INJECTABLES FOR TB TREATMENT AND PREVENTION

New drugs in clinical trials and long-acting injectable formulations have the potential to meet critical unmet needs in the treatment and prevention of tuberculosis, including shorter regimens, improved safety, and expanded options for drug-resistant tuberculosis. This presentation will provide an update on new drugs in early clinical development and describe how long-acting injectable formulations could…

THE STATE OF STI EPIDEMICS AND RESPONSE IN THE UNITED STATES

STIs in the United States are at an all-time high with reported cases of chlamydia, gonorrhea, and syphilis increasing for the sixth consecutive year in 2019. Yet not long ago, gonorrhea rates were at historic lows, and syphilis was close to elimination. Now congenital syphilis is rising dramatically, and the threat of antibiotic resistant gonorrhea…

CURRENT AND FUTURE RESEARCH IN STI VACCINES

More than one million sexually transmitted infections (STIs) are acquired every day worldwide. Untreated STIs have a significant impact on the sexual and reproductive health of populations and can lead to pregnancy complications, infertility, and cancers as well as increase HIV transmission. STIs and their complications are associated with stigma and considerable social and economic…

PAST AND FUTURE OF HIV VACCINES

Now over 40 years since the initial reports of AIDS, and despite tremendous strides in the development of, and broader global availability to, highly efficacious antiretroviral therapy, global rates of new HIV infections continue at an unacceptably high level. While progress is also being made in developing novel biomedical HIV prevention interventions, an efficacious HIV…

LESSONS LEARNED FROM THE AMP TRIAL: IS THE GLASS HALF FULL?

The AMP (Antibody Mediated Prevention) trial was the first study to show that a broadly neutralizing antibody (bnAb), VRC01, could prevent HIV-1 acquisition. However, this protection was incomplete, with VRC01 only blocking highly sensitive viruses. Here we will explore innate and selected resistance in breakthrough infections from this trial. Using an updated virus panel, we…